Capricor Therapeutics Inc CAPR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss
-
Capricor Therapeutics Rises as FDA Lifts Complete Response Letter, Resumes Review
-
Capricor Therapeutics Shares Rise After Positive Type A Meeting With FDA
-
Capricor: FDA Posting of Rejection Letter Didn't Include Response
-
Capricor Therapeutics Shares Plunge Premarket on FDA Setback
-
Capricor Therapeutics: FDA Rejects Bid for Deramiocel Approval
-
Capricor Therapeutics' Becker Muscular Dystrophy Drug Gets Orphan Drug Designation in U.S.
Trading Information
- Previous Close Price
- $20.35
- Day Range
- $19.00–20.49
- 52-Week Range
- $4.30–40.37
- Bid/Ask
- $18.70 / $20.00
- Shares Outstanding
- 57.91M
- Market Cap
- $1.11B
- Volume/Avg
- 26 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 231
- Website
- https://www.capricor.com
Valuation
|
Metric
|
CAPR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.96 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CAPR
|
|---|---|
Quick Ratio | 8.28 |
Current Ratio | 8.42 |
Interest Coverage | — |
Quick Ratio
CAPR
Profitability
|
Metric
|
CAPR
|
|---|---|
Return on Assets (Normalized) | −44.30% |
Return on Equity (Normalized) | −53.89% |
Return on Invested Capital (Normalized) | −51.26% |
Return on Assets
CAPR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|b??^@V | LOCK|%Npb | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$x@PR$ | LOCK|H?qY | $70B | |||
| argenx SE ADR
ARGX
| LOCK|TF%Lc^$ | LOCK|&%B | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|LBK%?l | LOCK|CbTJ | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|j>QJ?< | LOCK|r& | $37B | |||
| Moderna Inc
MRNA
| LOCK|VTx^DV | LOCK|kxt | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$<<>r!V | LOCK|$@LP | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|^>dQ<# | LOCK|%@ | $23B | |||
| Incyte Corp
INCY
| LOCK|<DTyYG< | LOCK|!H | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|WVy$@qK | LOCK|kB | $16B |
United States